Recently, JiuDian HongYang's API Prilocaine (Y20220000870) has been officially approved by CDE, and its registration status has been successfully changed to "A".

Prilocaine belongs to amide local anesthetics, which produces local anesthesia by blocking the ionic flow required for nerve impulse excitation and conduction and stabilizing the nerve cell membrane. The intensity and speed of anesthesia of prilocaine is similar to that of lidocaine, and the efficacy is better than that of procaine, but the duration is longer, the vasodilatory effect is weaker, and the toxicity is lower than that of lidocaine, and the accumulative nature is also smaller, which is a kind of drug with remarkable efficacy, high safety in clinical application, fewer adverse reactions, and better tolerability.

Prilocaine is usually combined with lidocaine as a topical preparation for local anesthesia, such as Lidocaine and Prilocaine cream, Lidocaine and Prilocaine Cutaneous spray solution， Lidocaine and Prilocaine periodontal gel. The market for prilocaine in medical aesthetic programs, dental anesthesia and other fields is expanding year by year, with rising sales and a broad market space.

Other anesthesia drugs for which Jiudian Hongyang has obtained marketing approval in CDE include lidocaine and lidocaine hydrochloride. The approval of prilocaine is a strong proof of our technical level and product quality, which not only further expands Hongyang's product line in the field of anesthesia drugs and optimizes our product structure, but also lays a solid foundation for future marketing, continuously improves the enterprise's efficiency and helps the high-quality development of anesthesia drug industry.